The acquisition marks a pivotal expansion for the company into the US market.
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
Taiwan’s largest pharmaceutical manufacturer, Bora Pharmaceuticals, has announced the approval by its Board of Directors for the acquisition of generics manufacturer, Upsher-Smith, which is based in Minnesota, USA, for a total of $210 million.
According to a Jan. 16, 2024 press release, this acquisition—the inaugural one for Bora in the US—marks a pivotal expansion for the company into the US market. Additionally, the acquisition creates additional capacity for Bora’s global contract development and manufacturing organization (CDMO) business and also completes the company’s capabilities to serve its customers throughout the entire value chain.
Upsher-Smith has two manufacturing facilities in Minnesota, one located in Plymouth and the other in Maple Grove. In combination, the two facilities are able to commercialize a broad range of dosage forms, including oral solid, powders, and liquids, in addition to packaging. Furthermore, the acquisition provides opportunities for Bora’s commercial sales operations in the US, TWi, through enhanced product development and marketing capabilities.
“This is a significant milestone for Bora Group, marking the most critical expansion of Bora’s presence in the US market and significantly enhancing Bora’s position as a global competitor with regard to its CDMO business and commercial Rx business,” said Bobby Sheng, chairman and CEO of Bora Group, in the press release. “Upsher-Smith’s competitiveness is a perfect match to Bora’s long-term growth—its newly-expanded, USFDA-approved manufacturing facilities, with a total capacity of 3.5 billion doses, will be Bora’s first local facility in the US, establishing a crucial stronghold for our global CDMO business.”
Closure of the acquisition is subject to the usual regulatory approvals. Once the deal has been officially closed, Bora will acquire 100% of Upsher-Smith through its wholly owned US subsidiary.
Source: Bora
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.